The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Additional public equities from our tracked universe.
Large-cap symbols investors frequently compare.
Start with the evergreen guides that matter most for this sector, then move back into the ticker page when you want to pressure-test the framework on a live name.
Our full report includes a DCF valuation model, 5-year financial analysis, competitive moat assessment, risk factors, and a clear BUY / HOLD / SELL recommendation — the same analysis hedge funds pay thousands for.